Want to see SE:SUS full AI Analyst Report?

Surgical Science Sweden AB (SUS) Price & Analysis

5 Followers

SUS Stock Chart & Stats

kr84.50

-kr3.20(-2.25%)

At close: Mar 06 4:00 PM EST

kr84.50

-kr3.20(-2.25%)

Day’s Range― - ―

52-Week Rangekr23.70 - kr162.60

Previous CloseN/A

Volume39.18K

Average Volume (3M)1.61M

Market Cap

kr1.57B

Enterprise Valuekr926.44M

Total Cash (Recent Filing)kr667.73M

Total Debt (Recent Filing)kr2.15M

Price to Earnings (P/E)29.9

Beta0.64

Next Earnings

Aug 19, 2026

EPS Estimate

0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.03

Shares Outstanding51,026,237

10 Day Avg. Volume583,608

30 Day Avg. Volume1,614,194

Financial Highlights & Ratios

PEG Ratio-0.50

Price to Book (P/B)0.39

Price to Sales (P/S)1.67

P/FCF Ratio24.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)2.05

Revenue Forecast (FY)kr995.98M

Bulls Say, Bears Say

Bulls Say

Exceptionally Strong Balance Sheet / Net CashNear-zero leverage and a substantial net cash position give durable financial flexibility. This lowers solvency and refinancing risk, supports multi-year R&D and production investments, and allows Surgical Science to tolerate lumpy project timing and pursue strategic initiatives without reliance on external debt.

Consistent Positive Cash Generation And Rebound In FCFSustained operating cash flow and a rebound in free cash flow underpin self-funding for capex and working capital. Reliable cash conversion supports investments (e.g., new production facility), funds product development, and reduces dependency on equity raises—strengthening long-term operational resilience.

Product And Customer Diversification In Robotics And EducationExpanding beyond a single robotics partner and strong educational product momentum (notably EMEA/U.K.) reduce customer concentration risk and broaden the addressable market. A diversified pipeline increases durable revenue optionality as surgical robotics adoption and simulation training secular trends continue to grow.

Bears Say

Material License Revenue Headwind From Intuitive ReversionA known SEK 60–90m hit to 2026 license revenues materially lowers the near-term revenue baseline and compresses multi-year growth visibility. Even with diversification, this structural contract change requires offsetting gains elsewhere or delays achievement of margin and revenue targets, stressing planning.

Significant FX Exposure And USD WeaknessHigh USD revenue share (~70%) creates recurring translation and transactional volatility; recent ~14% YoY USD weakness cut reported sales and trimmed gross margin (~2.2 pp). Persistent FX swings can destabilize reported profitability and complicate long-term forecasting and price-setting strategies.

Profitability Compression And Slightly Declining TTM RevenueEroding operating leverage and compressed margins reduce returns on a conservative capital base. Slight TTM revenue decline alongside lower EBIT and net margins indicates cost or mix pressures; absent sustained top-line growth, margin recovery is required to convert strong balance-sheet strength into superior long-term returns.

Surgical Science Sweden AB News

Surgical Science Sweden AB Signals Resilient Underlying Growth

Surgical Science Sweden AB (($SE:SUS)) has held its Q1 earnings call. Read on for the main highlights of...

2M ago

Surgical Science Sweden Balances Record Quarter With 2026 Risk

Surgical Science Sweden AB (($SE:SUS)) has held its Q4 earnings call. Read on for the main highlights of...

5M ago

Surgical Science price target lowered to SEK 40 from SEK 120 at Berenberg

Berenberg analyst Simon Jonsson lowered the firm’s price target on Surgical Science (SUSRF) to SEK 40 from SEK...

7M ago

Surgical Science Sweden AB’s Mixed Q3 2025 Earnings Call

Surgical Science Sweden AB (($SE:SUS)) has held its Q3 earnings call. Read on for the main highlights of...

8M ago

SUS

SUS FAQ

What was Surgical Science Sweden AB’s price range in the past 12 months?

Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr162.60 in the past 12 months.

What is Surgical Science Sweden AB’s market cap?

Surgical Science Sweden AB’s market cap is kr1.57B.

When is Surgical Science Sweden AB’s upcoming earnings report date?

Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 38 days.

How were Surgical Science Sweden AB’s earnings last quarter?

Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported kr0.37 earnings per share for the quarter, beating the consensus estimate of kr0.305 by kr0.065.

Is Surgical Science Sweden AB overvalued?

According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Surgical Science Sweden AB pay dividends?

Surgical Science Sweden AB does not currently pay dividends.

What is Surgical Science Sweden AB’s EPS estimate?

Surgical Science Sweden AB’s EPS estimate is 0.4.

How many shares outstanding does Surgical Science Sweden AB have?

Surgical Science Sweden AB has 51,026,237 shares outstanding.

What happened to Surgical Science Sweden AB’s price movement after its last earnings report?

Surgical Science Sweden AB reported an EPS of kr0.37 in its last earnings report, beating expectations of kr0.305. Following the earnings report the stock price went up 12.785%.

Which hedge fund is a major shareholder of Surgical Science Sweden AB?

Currently, no hedge funds are holding shares in SE:SUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Surgical Science Sweden AB

Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.